Regulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Update

Regulus Therapeutics Inc. (NASDAQ:RGLS) saw a significant decline in short interest in July. As of July 15th, there was short interest totalling 4,340,000 shares, a decline of 18.1% from the June 30th total of 5,300,000 shares. Based on an average daily volume of 817,600 shares, the days-to-cover ratio is currently 5.3 days. Currently, 8.2% of the shares of the stock are sold short.

Analyst Ratings Changes

Several research analysts have recently weighed in on RGLS shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research report on Tuesday, July 16th. Canaccord Genuity Group upped their price objective on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. Finally, StockNews.com started coverage on Regulus Therapeutics in a research report on Tuesday, April 16th. They set a “sell” rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Regulus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $11.75.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of RGLS. Bank of New York Mellon Corp bought a new position in shares of Regulus Therapeutics in the 2nd quarter worth about $352,000. Opaleye Management Inc. bought a new position in shares of Regulus Therapeutics in the 1st quarter worth about $490,000. RA Capital Management L.P. bought a new stake in Regulus Therapeutics in the 1st quarter valued at about $18,000,000. NEA Management Company LLC bought a new stake in Regulus Therapeutics in the 1st quarter valued at about $18,627,000. Finally, Vanguard Group Inc. increased its position in Regulus Therapeutics by 158.4% in the 1st quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after buying an additional 453,784 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics Price Performance

Regulus Therapeutics stock traded up $0.02 during mid-day trading on Friday, reaching $1.78. 1,509,376 shares of the company were exchanged, compared to its average volume of 835,089. The company has a fifty day simple moving average of $2.02 and a 200-day simple moving average of $1.98. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.14). As a group, research analysts expect that Regulus Therapeutics will post -0.59 EPS for the current fiscal year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.